Literature DB >> 18565862

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Naomi N Hunder1, Herschel Wallen, Jianhong Cao, Deborah W Hendricks, John Z Reilly, Rebecca Rodmyre, Achim Jungbluth, Sacha Gnjatic, John A Thompson, Cassian Yee.   

Abstract

We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1. 2008 Massachusetts Medical Society

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18565862      PMCID： PMC3277288          DOI： 10.1056/NEJMoa0800251

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


  20 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.

Authors:  Gang Zeng; Yong Li; Mona El-Gamil; John Sidney; Alexandro Sette; Rong-fu Wang; Steven A Rosenberg; Paul F Robbins
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

Review 3.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.

Authors:  Malcolm S Mitchell; Denise Darrah; David Yeung; Samuel Halpern; Anne Wallace; Joseph Voland; Vicky Jones; June Kan-Mitchell
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.

Authors:  Yongqing Li; Marie Bleakley; Cassian Yee
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

6.  Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.

Authors:  Hung T Khong; James C Yang; Suzanne L Topalian; Richard M Sherry; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2004 Nov-Dec       Impact factor: 4.456

7.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Authors:  Andreas Mackensen; Norbert Meidenbauer; Sandra Vogl; Monika Laumer; Jana Berger; Reinhard Andreesen
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

9.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

Authors:  Kunle Odunsi; Feng Qian; Junko Matsuzaki; Paulette Mhawech-Fauceglia; Christopher Andrews; Eric W Hoffman; Linda Pan; Gerd Ritter; Jeannine Villella; Bridget Thomas; Kerry Rodabaugh; Shashikant Lele; Protul Shrikant; Lloyd J Old; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-25       Impact factor: 11.205

10.  The central role of CD4(+) T cells in the antitumor immune response.

Authors:  K Hung; R Hayashi; A Lafond-Walker; C Lowenstein; D Pardoll; H Levitsky
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307
View more
  405 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

2.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 3.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

Review 4.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

8.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Authors:  Cyrille J Cohen; Jared J Gartner; Miryam Horovitz-Fried; Katerina Shamalov; Kasia Trebska-McGowan; Valery V Bliskovsky; Maria R Parkhurst; Chen Ankri; Todd D Prickett; Jessica S Crystal; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

9.  Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Authors:  Tao Dao; Dmitry Pankov; Andrew Scott; Tatyana Korontsvit; Victoriya Zakhaleva; Yiyang Xu; Jingyi Xiang; Su Yan; Manuel Direito de Morais Guerreiro; Nicholas Veomett; Leonid Dubrovsky; Michael Curcio; Ekaterina Doubrovina; Vladimir Ponomarev; Cheng Liu; Richard J O'Reilly; David A Scheinberg
Journal:  Nat Biotechnol       Date:  2015-09-21       Impact factor: 54.908

10.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.